Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Regulation of Ruxolitinib on matrix metalloproteinase in JAK2V617F positive myeloroliferative neoplasms cells].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi - 14 Feb 2017

Liu G M, Zhang L J, Fu J Z, Liang W T, Cheng Z Y, Bai P, Bian Y S, Wan J S

Abstract excerpt

Objective: To investigate the regulation of JAK2 tyrosine kinase inhibitor ruxolitinib on extracellular matrix metalloproteinase (MMP in JAK2V617F positive myeloproliferative neoplasms (MPN) cells. Methods: ①Forty cases of newly diagnosed JAK2V617F positive MPN patients and 15 healthy volunteers as control in Baoding No.1 Hospital between January 2012 and December 2015 were enrolled in this study. JAK2V617F/JAK2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Erythroblastic, Acute

Share to Matrix Metalloproteinase 2

Share to Matrix Metalloproteinase 9

Share to Myeloproliferative Disorders

Share to Nitriles

Share to Pyrazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 28279039
DOI: 10.3760/cma.j.issn.0253-2727.2017.02.011
PMCID: PMC7354179

Genes

JAK2
CCK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Regulation of Ruxolitinib on matrix metalloproteinase in JAK2V617F positive myeloroliferative neoplasms cells].PMID 28279039Read ↗

[Research Progress on Effect of JAK Inhibitors on Myelofibrosis- Review].Semantic proximity Read ↗

[Anti-angiogenic effect of interferon on JAK2V617F positive myeloproliferative neoplasms and its anti-angiogenic mechanisms].Semantic proximity Read ↗

Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells.Semantic proximity Read ↗

[Effect of IFN-α2b on COX-2 and Angiogenesis in JAK2V617F Mutation Myeloproliferative Neoplasms].Semantic proximity Read ↗

Effects of Ruxolitinib on Immune Checkpoint Molecule Expression in JAK2 V617F-Positive Cells.Semantic proximity Read ↗

[Inhibitors of JAK2/STAT Signaling Pathway and Hematologic Malignancies-Review].Semantic proximity Read ↗

Effects of Ruxolitinib on Myeloproliferative Neoplasms via the Negative Regulators.Semantic proximity Read ↗

Janus activated kinase inhibition in myelofibrosis.Semantic proximity Read ↗

Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.Semantic proximity Read ↗

Janus kinase inhibition and symptom control in myeloproliferative neoplasmsSemantic proximity Read ↗

Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.Semantic proximity Read ↗

[JAK2V617F mutation and TNF-α expression in myeloproliferative neoplasms and their correlation].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.